KR20240093562A - 수의학적 용도를 위한 항-il31 항체 - Google Patents

수의학적 용도를 위한 항-il31 항체 Download PDF

Info

Publication number
KR20240093562A
KR20240093562A KR1020247015851A KR20247015851A KR20240093562A KR 20240093562 A KR20240093562 A KR 20240093562A KR 1020247015851 A KR1020247015851 A KR 1020247015851A KR 20247015851 A KR20247015851 A KR 20247015851A KR 20240093562 A KR20240093562 A KR 20240093562A
Authority
KR
South Korea
Prior art keywords
ser
leu
antibody
thr
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247015851A
Other languages
English (en)
Korean (ko)
Inventor
샤이어 지안 리
람 누엔
항준 잔
Original Assignee
엘랑코 유에스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘랑코 유에스 인코포레이티드 filed Critical 엘랑코 유에스 인코포레이티드
Priority claimed from PCT/US2018/017623 external-priority patent/WO2018156367A1/en
Publication of KR20240093562A publication Critical patent/KR20240093562A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247015851A 2017-02-24 2018-02-09 수의학적 용도를 위한 항-il31 항체 Pending KR20240093562A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762463543P 2017-02-24 2017-02-24
US62/463,543 2017-02-24
USPCT/US2017/023788 2017-03-23
PCT/US2017/023788 WO2018156180A1 (en) 2017-02-24 2017-03-23 Anti-il31 antibodies for veterinary use
KR1020197025631A KR20190127703A (ko) 2017-02-24 2018-02-09 수의학적 용도를 위한 항-il31 항체
PCT/US2018/017623 WO2018156367A1 (en) 2017-02-24 2018-02-09 Anti-il31 antibodies for veterinary use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197025631A Division KR20190127703A (ko) 2017-02-24 2018-02-09 수의학적 용도를 위한 항-il31 항체

Publications (1)

Publication Number Publication Date
KR20240093562A true KR20240093562A (ko) 2024-06-24

Family

ID=63245488

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197025631A Ceased KR20190127703A (ko) 2017-02-24 2018-02-09 수의학적 용도를 위한 항-il31 항체
KR1020247015851A Pending KR20240093562A (ko) 2017-02-24 2018-02-09 수의학적 용도를 위한 항-il31 항체

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020197025631A Ceased KR20190127703A (ko) 2017-02-24 2018-02-09 수의학적 용도를 위한 항-il31 항체

Country Status (11)

Country Link
US (7) US10093731B2 (enExample)
EP (1) EP3585429A4 (enExample)
JP (3) JP7277370B2 (enExample)
KR (2) KR20190127703A (enExample)
CN (2) CN110769851B (enExample)
AU (2) AU2018224711B2 (enExample)
BR (1) BR112019017308A2 (enExample)
CA (1) CA3053525A1 (enExample)
MA (1) MA47609A (enExample)
MX (1) MX2024012304A (enExample)
WO (1) WO2018156180A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3448391T3 (pl) 2016-04-27 2024-09-16 AbbVie Manufacturing Management Unlimited Company Sposoby leczenia chorób, w których jest szkodliwa aktywność il-13, przy zastosowaniu przeciwciała anty-il-13
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CA3054389A1 (en) * 2017-03-07 2018-09-13 Universitat Zurich Treatment of pruritus in horses
EP3765069A1 (en) 2018-03-16 2021-01-20 Zoetis Services LLC Peptide vaccines against interleukin-31
US20220324960A1 (en) * 2019-08-29 2022-10-13 Kindred Biosciences, Inc. Anti-IL31 Antibodies for Veterinary Use
AU2020409583A1 (en) 2019-12-20 2022-06-09 Intervet International B.V. Canine interleukin-4 receptor alpha antibodies
BR112022011629A2 (pt) * 2019-12-20 2022-09-13 Intervet Int Bv Anticorpos biespecíficos caninizados para tratar dermatite atópica
CA3175921A1 (en) * 2020-04-17 2021-10-21 Zoetis Services Llc Canine antibody variants
US20230312702A1 (en) * 2020-04-22 2023-10-05 Kindred Biosciences, Inc. Long-acting anti-il31 antibodies for veterinary use
AU2021306179A1 (en) 2020-07-10 2023-03-02 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
JP2023545183A (ja) 2020-10-15 2023-10-26 インターベット インターナショナル ベー． フェー． イヌインターロイキン－３１受容体アルファに対するイヌ化抗体
EP4247848A4 (en) * 2020-11-23 2025-10-01 Scout Bio Inc ANTIGEN-BINDING MOLECULES AND THEIR USES
BR112023016043A2 (pt) * 2021-02-22 2023-12-05 Zoetis Services Llc Modelo de prurido induzido por il-31 de cavalo
US20250325630A1 (en) 2021-08-20 2025-10-23 Intervet Inc. Homodimer fusion proteins for treating atopic dermatitis
CA3239826A1 (en) 2021-12-16 2023-06-22 Mohamad Morsey Caninized antibodies to canine interleukin-31 receptor alpha ii
EP4642795A2 (en) 2022-12-27 2025-11-05 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
CN120603845A (zh) 2022-12-27 2025-09-05 因外泰克斯公司 与新生儿Fc受体(FcRn)的结合经改变的多肽及使用方法
EP4652195A2 (en) 2023-01-20 2025-11-26 Invetx, Inc. Bispecific binding agents for use in companion animals
EP4665459A1 (en) 2023-02-13 2025-12-24 Intervet International B.V. Canine antibodies to canine il-13
EP4665756A1 (en) 2023-02-13 2025-12-24 Intervet International B.V. Canine antibodies to canine il-4
CN120865402A (zh) * 2023-11-27 2025-10-31 宁波贝安生物科技有限公司 抗il-31的抗体及其用途
CN118667001B (zh) * 2024-07-16 2025-05-06 华中农业大学 一种抗犬il-31的单克隆抗体及其应用
CN120209126B (zh) * 2025-05-28 2025-09-16 中国医学科学院医学生物学研究所 人偏肺病毒单克隆抗体及其应用

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW205553B (enExample) 1991-04-25 1993-05-11 Chugai Pharmaceutical Co Ltd
JP3919830B2 (ja) 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
CA2163976C (en) 1993-05-28 2010-06-29 Didier J. Leturcq Methods and compositions for inhibiting cd14 mediated cell activation
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU2001236073B2 (en) 2000-03-03 2006-10-19 Kyowa Kirin Co., Ltd. Gene recombinant antibody and its fragment
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
EP1485126A4 (en) 2001-12-21 2007-03-21 Idexx Lab Inc DOG IMMUNOGLOBULIN VARIABLE DOMAINS, DOG ANTIBODIES, AND METHOD FOR THEIR PRODUCTION AND USE
ATE536406T1 (de) 2002-01-18 2011-12-15 Zymogenetics Inc Neuartiger zytokin-zcytor17-ligand
DK1551876T3 (da) 2002-10-16 2011-06-14 Purdue Pharma Lp Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
JP2008528039A (ja) 2005-01-28 2008-07-31 ザイモジェネティクス，インコーポレイティド Ｉｌ−３１の均質調製物
EP1858924A1 (en) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
CA2595939C (en) 2005-02-14 2014-08-19 Zymogenetics Inc. Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists
JP2008532559A (ja) 2005-03-19 2008-08-21 メディカル リサーチ カウンシル ウイルス感染の治療及び予防又は治療及び予防の改善
WO2006104989A2 (en) 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
RU2444528C2 (ru) 2005-05-06 2012-03-10 Займоджинетикс, Инк. Моноклональные антитела против il-31 и способы применения
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
AU2007254715B2 (en) 2005-05-06 2013-08-29 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
CN1896229A (zh) * 2005-06-29 2007-01-17 北京天广实生物技术有限公司 一种新型抗cd20嵌合抗体的制备及其用途
RU2008120027A (ru) * 2005-10-21 2009-11-27 Мерк энд Ко., Инк. (US) Анти-addl моноклональное антитело и его применение
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
PT2594586E (pt) 2006-09-01 2014-11-26 Zymogenetics Inc Anticorpos monoclonais de il-31 e métodos de utilização
JP2010502224A (ja) 2006-09-08 2010-01-28 アボット・ラボラトリーズ インターロイキン１３結合タンパク質
AU2007319604B2 (en) 2006-10-19 2011-03-24 Csl Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
AU2008204823A1 (en) 2007-01-10 2008-07-17 Zymogenetics, Inc Methods of using IL-31 to treat airway hyper-responsiveness and asthma
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
ES2660036T3 (es) 2007-12-07 2018-03-20 Zymogenetics, Inc. Moléculas de anticuerpo humanizadas específicas para IL-31
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
BRPI0917459B1 (pt) 2008-08-20 2017-09-12 Zoetis Services Llc N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
WO2010027488A2 (en) 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies
MX2011000455A (es) 2008-11-07 2011-02-25 Galaxy Biotech Llc Anticuerpos monoclonales especificos al receptor 2 del factor de crecimiento de fibroblastos.
WO2011065935A1 (en) 2009-11-24 2011-06-03 Cornell University Methods for monoclonal antibody production
US20110287454A1 (en) 2008-11-25 2011-11-24 Cornell University Methods for monoclonal antibody production
AU2013203075A1 (en) * 2008-11-28 2013-05-02 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
US20110165063A1 (en) 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
AU2010264764A1 (en) 2009-06-22 2011-12-08 Peptcell Limited Pharmaceutical agent
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
KR20230044026A (ko) 2010-02-24 2023-03-31 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
PL2571532T3 (pl) 2010-05-14 2017-10-31 Abbvie Inc Białka wiążące IL-1
UY33578A (es) 2010-08-31 2012-03-30 Sanofi Sa PÉPTIDO O COMPLEJO PEPTÍDICO QUE SE UNE A INTEGRINA a(ALFA) Y MÉTODOS Y USOS QUE IMPLICAN A LOS MISMOS
US9255925B2 (en) 2010-10-20 2016-02-09 Medical Diagnostic Laboratories, Llc ELISA detection of urine DEK to predict and diagnose bladder cancer in humans
RU2620071C2 (ru) 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
AU2012248470B2 (en) 2011-04-25 2016-10-27 Daiichi Sankyo Company, Limited Anti-B7-H3 antibody
AR086250A1 (es) 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
SG194793A1 (en) 2011-05-06 2013-12-30 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
ES2643694T3 (es) 2011-05-19 2017-11-23 Inserm (Institut National De La Santé Et De La Recherche Medicale) Anticuerpos anti-HER3 humanos y sus usos
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
MX364591B (es) 2013-03-15 2019-05-02 Regeneron Pharma Antagonistas de il-33 y usos de estos.
RS56814B1 (sr) 2013-03-15 2018-04-30 Bayer Healthcare Llc Varijante anti-tfpi antitela sa diferencijalnim vezivanjem duž ph opsega zarad poboljšanja farmakokinetike
JP6671276B2 (ja) 2013-03-27 2020-03-25 セダーズ−シナイ メディカル センター Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
EP3003350B1 (en) 2013-05-27 2018-02-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Targeted modulation of macrophages
MY199321A (en) * 2013-05-30 2023-10-24 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins
WO2014208645A1 (ja) 2013-06-28 2014-12-31 中外製薬株式会社 そう痒を伴う疾患に罹患した患者のｉｌ－３１アンタゴニストによる治療に対する応答を予測する方法
WO2015002985A2 (en) 2013-07-01 2015-01-08 University Of Maryland Fc coupled compositions and methods of their use
WO2015042596A1 (en) * 2013-09-23 2015-03-26 Kindred Biosciences, Inc Treatment of atopic dermatitis in non-human animals
WO2015067755A2 (en) 2013-11-07 2015-05-14 Novo Nordisk A/S Novel methods and antibodies for treating coagulapathy
WO2015086830A1 (en) 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
CN103965357B (zh) 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
JP2018504911A (ja) 2015-01-29 2018-02-22 ネックスヴェット オーストラリア プロプライエタリー リミテッド 治療及び診断剤
CN104710528B (zh) * 2015-03-13 2019-02-15 西北农林科技大学 一种特异性结合PRRS病毒非结构蛋白Nsp9纳米抗体及其应用
WO2016167263A1 (ja) 2015-04-14 2016-10-20 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
JP6912384B2 (ja) * 2015-04-22 2021-08-04 キュアバック アーゲー 癌疾患の処置のための、ｒｎａ含有組成物
CN107921144B (zh) 2015-06-20 2023-11-28 杭州多禧生物科技有限公司 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物
WO2017025698A1 (en) 2015-08-11 2017-02-16 Queen Mary University Of London Bispecific, cleavable antibodies
TW201729810A (zh) 2015-10-26 2017-09-01 札爾科製藥公司 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法
US11041017B2 (en) * 2016-03-29 2021-06-22 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
PH12018502203B1 (en) 2016-04-15 2024-05-15 Immunext Inc Anti-human vista antibodies and use thereof
PH12018501777B1 (en) 2016-04-20 2022-08-10 Hangzhou Dac Biotech Co Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule
WO2018073185A1 (en) 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
CN110099682B (zh) 2016-11-14 2023-03-31 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2018156367A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CA3058712C (en) 2017-04-06 2023-04-18 Hangzhou Dac Biotech Co., Ltd Conjugation of a cytotoxic drug with bis-linkage
TW202515920A (zh) 2017-04-11 2025-04-16 美商因荷布瑞克斯生物科學公司 具有經受限cd3結合的多重特異性多肽構築體及使用其之方法
WO2018195388A1 (en) 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
EP3483180A1 (en) 2017-11-14 2019-05-15 Affilogic Multi specific molecules
CA3085318A1 (en) 2017-12-11 2019-06-20 Ubi Ip Holdings Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
CN111093707A (zh) 2017-12-31 2020-05-01 杭州多禧生物科技有限公司 含支链连接体的Tubulysin同系物偶联物
CA3093539A1 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
US20210009678A1 (en) 2018-03-23 2021-01-14 North Carolina State University Methods and compositions for allergic disorders
KR20210006913A (ko) 2018-04-11 2021-01-19 인히브릭스, 인크. 제한된 ｃｄ3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
CN112272669A (zh) 2018-07-05 2021-01-26 杭州多禧生物科技有限公司 横交联吡咯并苯二氮杂*二聚体（pbd）衍生物及其偶联物
CA3111854A1 (en) 2018-09-14 2020-03-19 Kindred Biosciences, Inc. Anti-il4 receptor antibodies for veterinary use
MX2021004069A (es) 2018-10-12 2021-06-08 Hangzhou Dac Biotech Co Ltd Enlazadores de conjugacion que contienen el grupo 2,3-diaminosuccinilo.
MX2021004313A (es) 2018-10-18 2021-05-27 Kindred Biosciences Inc Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
WO2020086886A1 (en) 2018-10-25 2020-04-30 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN120904316A (zh) 2018-12-27 2025-11-07 伊兰科美国公司 兽用IgG Fc变体
MX2021008144A (es) 2019-01-03 2021-10-13 Invetx Inc Composiciones para aumentar la media vida de un agente terapeutico en caninos y metodos de uso.
NZ779060A (en) 2019-01-31 2024-11-29 Hangzhou Dac Biotech Co Ltd A conjugate of an amanita toxin with branched linkers
PH12021552123A1 (en) 2019-03-21 2022-08-22 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
BR112021019076A2 (pt) 2019-03-25 2021-11-30 Alteogen Inc Composição farmacêutica e formulação para injeção subcutânea compreendendo uma variante de hialuronidase ph20 humana
EP3986476A4 (en) 2019-06-24 2023-11-15 Hangzhou Dac Biotech Co., Ltd. FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL BINDING MOLECULE
JP2022539076A (ja) 2019-06-24 2022-09-07 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 分岐連結体を有する細胞結合分子と細胞毒性剤との共役体
US20220324960A1 (en) 2019-08-29 2022-10-13 Kindred Biosciences, Inc. Anti-IL31 Antibodies for Veterinary Use
EP4047019A4 (en) 2019-12-13 2023-11-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ANTI-TSLP ANTIBODIES AND USES THEREOF
BR112022011629A2 (pt) 2019-12-20 2022-09-13 Intervet Int Bv Anticorpos biespecíficos caninizados para tratar dermatite atópica
CN115135669A (zh) 2020-02-19 2022-09-30 艾迪沃有限责任公司 修饰的Fc区
CA3169301A1 (en) 2020-03-18 2021-09-23 Shyr Jiann Li Anti-il4 receptor antibodies for veterinary use
CA3175921A1 (en) 2020-04-17 2021-10-21 Zoetis Services Llc Canine antibody variants
JP2023522676A (ja) 2020-04-22 2023-05-31 キンドレッド バイオサイエンシズ インコーポレイテッド 動物用のｉｌ４／ｉｌ１３受容体分子
US20230312702A1 (en) * 2020-04-22 2023-10-05 Kindred Biosciences, Inc. Long-acting anti-il31 antibodies for veterinary use
US20230241241A1 (en) 2020-06-19 2023-08-03 Hangzhou Dac Biotech Co., Ltd. Conjugates of a cell-binding molecule with camptothecin analogs
AU2021306179A1 (en) 2020-07-10 2023-03-02 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
EP4209227A4 (en) 2020-09-01 2024-05-29 Chugai Seiyaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF PRURITUS IN DIALYSIS CONTAINING AN IL-31 ANTAGONIST AS ACTIVE INGREDIENT

Also Published As

Publication number Publication date
US10093731B2 (en) 2018-10-09
WO2018156180A1 (en) 2018-08-30
MX2024012304A (es) 2024-11-08
US20230365672A1 (en) 2023-11-16
AU2018224711B2 (en) 2024-11-14
JP2025138636A (ja) 2025-09-25
US12435132B2 (en) 2025-10-07
US20190169285A1 (en) 2019-06-06
AU2018224711A1 (en) 2019-09-05
US20210163587A1 (en) 2021-06-03
JP7277370B2 (ja) 2023-05-18
CN117603350A (zh) 2024-02-27
US11697683B2 (en) 2023-07-11
MA47609A (fr) 2020-01-01
US11673946B2 (en) 2023-06-13
RU2019129618A (ru) 2021-03-24
KR20190127703A (ko) 2019-11-13
US20180244766A1 (en) 2018-08-30
US12448438B2 (en) 2025-10-21
CN110769851B (zh) 2023-12-08
RU2019129618A3 (enExample) 2021-06-23
CA3053525A1 (en) 2018-08-30
BR112019017308A2 (pt) 2020-04-14
US20200062840A1 (en) 2020-02-27
JP7716441B2 (ja) 2025-07-31
AU2025201182A1 (en) 2025-03-13
EP3585429A1 (en) 2020-01-01
JP2023109811A (ja) 2023-08-08
US20180244767A1 (en) 2018-08-30
CN110769851A (zh) 2020-02-07
US10150810B2 (en) 2018-12-11
JP2020511123A (ja) 2020-04-16
EP3585429A4 (en) 2020-12-02
US20240101660A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
US12448438B2 (en) Anti-IL31 antibodies for veterinary use
US20220049002A1 (en) Anti-IL4 Receptor Antibodies for Veterinary Use
WO2018156367A1 (en) Anti-il31 antibodies for veterinary use
US20230312702A1 (en) Long-acting anti-il31 antibodies for veterinary use
US20220185879A1 (en) IL17A Antibodies and Antagonists for Veterinary Use
JP7671275B2 (ja) 動物用の抗ｉｌ３１抗体
RU2795485C2 (ru) Анти-il31 антитела для применения в ветеринарии
HK40088130A (zh) 长效兽用抗il31抗体

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E12 Pre-grant re-examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E12-REX-PX0901 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701